510(k) Report

510(k) · Cleared

Cleared

VFE

K983107510(k) TraditionalCleared Oct 22, 199848-day reviewClass II21 CFR 864.7290

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Ramco Laboratories, Inc. · GGP Test, Qualitative And Quantitative Factor Deficiency

Cleared on Oct 22, 1998 as substantially equivalent to K861159 (Ramco Laboratories, Inc., 1986) after a 48-day review. Its family tree reaches back 1 generation to 1986.

Decided
Oct 22, 1998
Review
48 days
Class
Class II
Product code
GGP
Recalls
None
Predicates
1

Its longest line of descent runs back 1 generation to K861159 (1986). No later device cites it as a predicate yet.

K861159 · Spectro VWF · Ramco Laboratories, Inc. · 19861985199019952000
K861159 · Spectro VWF · Ramco Laboratories, Inc. · 19860
  1. Root · 1 generation backK861159 Spectro VWFRamco Laboratories, Inc. · 1986
  2. This deviceK983107 VFERamco Laboratories, Inc. · 1998
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−1K861159Spectro VWFRamco Laboratories, Inc.1986—
0 (this device)K983107VFERamco Laboratories, Inc.1998—
FIG. 1 — Lineage of K983107, 1986–1998Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in GGP? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new GGP device

  1. #1 K251440 CRYOcheck Chromogenic Factor VIIIscore 10.5 · 3 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K861159Spectro VWF
Summary page 1
…Antigen Assay VFE Enzyme Assay for von Willebrand Factor Enzyme Linked Immunoassay SPECTRO vWF Ramco Laboratories, Inc. 4507 Mt. Vernon Houston, Texas 77006 510(k) #K861159 45 Description of Device: VFE is an enzyme immunoassay, in microplate format, intended for the in vitro quantif…
Ramco Laboratories, Inc.1986—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • Its one ancestor has no recall.

How does its category compare?

All GGP devices

GGP Test, Qualitative And Quantitative Factor Deficiency: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · GGP

1in 2025

2007: 32008: 22009: 12011: 12014: 12018: 12019: 12020: 22022: 22023: 22025: 1
2007high 3 (2007) · low 0 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · GGP

153in 2007

2007: 153 days median
2007high 153 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · GGP

1in 2017

2007: 22010: 12012: 22015: 22017: 12026 (partial year): 1
2007high 2 (2007) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · GGP

3in 2025

2012: 42014: 12015: 12017: 32018: 32019: 12021: 22022: 42025: 3
2007high 4 (2012) · low 0 (2007)2025

MAUDE reports naming product code GGP, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007315320
20082—00
20091—00
20100—10
20111—00
20120—24
20130—00
20141—01
20150—21
20160—00
20170—13
20181—03
20191—01
20202—00
20210—02
20222—04
20232—00
20240—00
20251—03
20260—1—

What is it indicated for?

The VFE assay is an in vitro enzyme immunoassay

for quantifying the concentration of von Willebrand

Factor Antigen in human plasma to aid in

differentiating patients with von Willebrand disease

from those with Classical Hemophilia A.

Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.

Cite this page

510(k) Report. “K983107: VFE.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K983107

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026